Microsporidiosis is an infection caused by obligate intracellular, spore-forming organisms (microsporidia) related to fungi. Enterocytozoon bieneusi and Encephalitozoon intestinalis are the most clinically relevant species. The disease predominantly affects immunocompromised hosts, especially those with advanced HIV (CD4 <100 cells/mm³), organ transplant recipients, and patients on immunosuppressive therapy. [1-2]
1. History
- Diarrhea characterization: Intermittent, copious, watery, non-bloody diarrhea — ask about frequency, volume, duration, and chronicity (>2 weeks raises suspicion) [3]
- Associated GI symptoms: Crampy abdominal pain, nausea, weight loss, malabsorption symptoms (steatorrhea, bloating); fever is uncommon [3]
- Ocular symptoms: Eye redness, tearing, foreign body sensation, photophobia (keratoconjunctivitis) [2]
- Systemic symptoms: Sinusitis, cough/dyspnea (respiratory involvement), muscle pain (myositis), neurologic changes (encephalitis) [2-3]
- Timing and progression: Chronic or relapsing course in immunocompromised; self-limited in immunocompetent travelers [3-4]
- Important negatives: Absence of bloody stool (helps distinguish from invasive bacterial diarrhea), absence of fever
2. Alarm Features
- Severe dehydration, hemodynamic instability, or electrolyte derangements from profuse diarrhea [3]
- Signs of disseminated disease: encephalitis (altered mental status, seizures), hepatitis (jaundice), nephritis [2-3]
- Significant wasting/failure to thrive, especially in pediatric or HIV patients [3]
- Visual changes suggesting stromal keratitis (risk of corneal perforation in immunocompetent hosts post-trauma) [2]
- New neurologic deficits suggesting CNS involvement (Trachipleistophora, E. cuniculi) [2]
3. Medications
Primary treatments
- Albendazole 400 mg PO BID (adults) — effective for Encephalitozoon spp. and most species except E. bieneusi and V. corneae [2]
- Fumagillin 60 mg/day PO — effective for E. bieneusi; unavailable for systemic use in the US [2]
- Nitazoxanide 500 mg PO BID × ≥14 days — reasonable alternative for E. bieneusi if fumagillin unavailable (limited efficacy with low CD4) [2]
- Itraconazole 400 mg/day + albendazole — for disseminated Trachipleistophora or Anncaliia [2]
Ocular infection
Contraindicated/ineffective
- Metronidazoleatovaquone[2-3]
Pregnancy cautions
- Albendazole: avoid first trimester [2]
- Systemic fumagillin: contraindicated in pregnancy (antiangiogenic) [2]
Key drug interaction: ART is the cornerstone of treatment in HIV patients — immune reconstitution is the primary driver of clearance [2-3]
4. Diet
- Aggressive oral rehydration with electrolyte-containing solutions for diarrheal illness [3]
- Nutritional supplementation — high-calorie, high-protein diet to counteract malabsorption and wasting [2-3]
- Avoid contaminated water sources (waterborne transmission documented); boiled or filtered water recommended for immunocompromised patients [2-3]
- No specific dietary triggers; long-term management focuses on maintaining nutritional status during chronic infection
5. Review of Systems
- GI: Diarrhea, abdominal cramping, bloating, weight loss, steatorrhea
- Ophthalmologic: Eye pain, redness, blurred vision, photophobia
- Respiratory: Cough, dyspnea, sinus congestion (E. hellem) [2-3]
- Neurologic: Headache, confusion, seizures (encephalitis — E. cuniculi, Trachipleistophora) [2]
- Musculoskeletal: Myalgias, muscle weakness (myositis — Pleistophora, Anncaliia, Trachipleistophora) [2]
- Genitourinary: Dysuria, urinary frequency (nephritis, cystitis, prostatic abscess — E. hellem) [3]
- Hepatobiliary: RUQ pain, jaundice (cholangitis — E. bieneusi; hepatitis — E. cuniculi) [2-3]
6. Collateral History and Family History
- HIV status and ART adherence — non-adherence is a major risk factor for microsporidiosis [5]
- CD4 count and viral load — clinical disease most common at CD4 <100 cells/mm³ [2]
- Transplant history — organ transplant recipients at risk; clusters from latent infection in transplanted organs documented [1]
- Immunosuppressive medications — anti-TNF-α therapy, chemotherapy [1]
- Travel history — endemic areas, waterborne exposure [3]
- Animal exposure — zoonotic transmission possible [2-3]
- Contact lens use — risk factor for microsporidial keratitis in immunocompetent hosts [2-3]
- No significant hereditary predisposition
7. Risk Factors
- Advanced HIV/AIDS with CD4 <100 cells/mm³ (strongest risk factor) [2]
- Non-adherence to ART [5]
- Solid organ transplantation [1-2]
- Immunosuppressive therapy (anti-TNF-α, chemotherapy) [1]
- Age ≥60 years [5]
- Contaminated water exposure (waterborne/foodborne transmission) [2-3]
- Contact lens wear (ocular microsporidiosis) [2]
- Travel to endemic regions [3]
- Malnutrition [3]
8. Differential Diagnosis
Cannot-miss diagnoses in immunocompromised patients with chronic diarrhea:
- Cryptosporidiosis — watery diarrhea, acid-fast positive oocysts on stool; often co-occurs with microsporidiosis [6-7]
- CMV colitis — bloody diarrhea, diagnosed by colonoscopy with biopsy showing owl-eye inclusions [6]
- Mycobacterium avium complex (MAC) — diarrhea with systemic symptoms, diagnosed by blood cultures [6]
- Cystoisospora belli — watery diarrhea, eosinophilia, acid-fast oocysts [6]
Other important differentials
- Giardiasis — bloating, steatorrhea, foul-smelling stool
- Cyclospora cayetanensis — prolonged watery diarrhea, travel history
- HIV enteropathy — diagnosis of exclusion after infectious workup negative
- ART-related diarrhea — medication side effect (especially protease inhibitors) [6]
- Clostridium difficile — antibiotic exposure, toxin-positive stool
Distinguishing features of microsporidiosis: Non-bloody, watery diarrhea; absence of fever; requires special staining (modified trichrome, calcofluor white) — standard O&P will miss it [2-3]
9. Past Medical History
- HIV/AIDS — most critical; document CD4 nadir, current CD4, viral load, ART regimen
- Prior opportunistic infections — suggests degree of immunosuppression
- Organ transplantation — type, immunosuppressive regimen
- Malignancy/chemotherapy
- Previous episodes of microsporidiosis — relapse common if immune reconstitution not achieved [3]
- Ocular surgery or trauma — risk for stromal keratitis in immunocompetent hosts [2]
10. Physical Exam
- Vitals: Tachycardia, hypotension (dehydration); fever typically absent
- General: Cachexia, wasting, signs of malnutrition
- Abdomen: Diffuse mild tenderness, hyperactive bowel sounds; no peritoneal signs (if present, consider alternative diagnosis)
- Eyes: Conjunctival injection, punctate epithelial keratopathy on slit-lamp exam (keratoconjunctivitis) [2]
- Skin: Turgor assessment for dehydration
- Neurologic: Mental status changes, focal deficits (if encephalitis suspected) [2]
- Musculoskeletal: Proximal muscle tenderness/weakness (myositis) [2]
- Hepatobiliary: RUQ tenderness, jaundice (cholangitis/hepatitis) [3]
11. Lab Studies
- Stool microscopy with special stains (must be specifically requested):
- Modified trichrome stain (Weber's) — spores appear pink-red with equatorial belt-like stripe; high specificity (100%) [3][8-9]
- Calcofluor white or Uvitex 2B (fluorescent brighteners) — most sensitive screening stain; some false positives from yeast [2][8][10]
- Stool PCR — highest sensitivity (100%) and specificity (97.9%); enables speciation; available at CDC [3][8-9]
- Urine sediment microscopy — for Encephalitozoon or Trachipleistophora in disseminated disease [2-3]
- Basic metabolic panel — electrolytes, BUN/creatinine (dehydration, renal involvement)
- CBC — baseline; monitor for thrombocytopenia if fumagillin used [3]
- LFTs — if hepatitis or cholangitis suspected
- CD4 count and HIV viral load — essential for guiding treatment duration [2]
- Blood cultures — to rule out MAC in HIV patients with diarrhea [6]
12. Imaging
- Generally not required for uncomplicated GI microsporidiosis
- Abdominal ultrasound or MRCP — if cholangitis suspected (biliary dilation, gallbladder wall thickening with E. bieneusi) [3]
- CT abdomen — may show bowel wall thickening, mesenteric lymphadenopathy in disseminated disease; primarily used to exclude other pathology
- MRI brain — if encephalitis suspected (E. cuniculi, Trachipleistophora) [2]
13. Special Tests
- Transmission electron microscopy (TEM) — historical gold standard; identifies polar tube (pathognomonic); expensive, time-consuming, requires expertise [2][11]
- Small bowel biopsy (endoscopic) — indicated if stool exams negative and clinical suspicion remains high, or chronic diarrhea >2 months with negative stool workup [2-3]
- Touch preparations for rapid diagnosis (within 24 hours) [3]
- Tissue stains: Giemsa, Brown-Hopps Gram stain, Warthin-Starry silver, Chromotrope 2A [2]
- Species-specific immunofluorescent antibody (IFA) assays — available for some species [3]
- Slit-lamp examination — for suspected ocular microsporidiosis [2]
- Diagnostic paradigm: Screen stool with calcofluor white → confirm with modified trichrome → speciate with PCR [8][10]
14. ECG
- Not routinely indicated
- Consider if cardiac involvement suspected (Trachipleistophora — rare cardiac disease reported) [3]
- Baseline ECG if initiating medications with potential cardiac interactions (itraconazole — QT prolongation risk)
15. Assessment
Typical presentation: Immunocompromised patient (HIV with CD4 <100) presenting with chronic, watery, non-bloody diarrhea, weight loss, and malabsorption without fever. [2-3]
Atypical presentations
- Keratoconjunctivitis in contact lens wearers (immunocompetent) [2]
- Self-limited traveler's diarrhea in immunocompetent hosts [4]
- Disseminated disease with multi-organ involvement (encephalitis, hepatitis, myositis, nephritis) [2]
Severity stratification
- Mild: Intermittent diarrhea, adequate oral intake, stable weight
- Moderate: Persistent diarrhea with dehydration, electrolyte abnormalities, weight loss
- Severe: Disseminated disease, wasting syndrome, organ-specific complications (encephalitis, cholangitis), hemodynamic instability
Complications: Severe malnutrition/wasting, cholangitis/sclerosing cholangiopathy, corneal scarring, encephalitis, death (significant mortality in profoundly immunosuppressed patients) [1][12]
16. Treatment Plan
Initial stabilization
- IV fluid resuscitation and electrolyte correction for dehydrated patients [2-3]
- Antimotility agents (loperamide) for symptom control if needed [2]
- Nutritional supplementation for malnourished/wasting patients [2]
Definitive therapy (species-dependent)
Treatment duration: Continue albendazole until CD4 >200 cells/mm³ sustained for ≥3 months after ART initiation and symptom resolution. [2]
Monitoring: CBC (thrombocytopenia with fumagillin), LFTs (albendazole hepatotoxicity), CD4 count, stool clearance [3]
17. Disposition
Admission criteria
- Severe dehydration requiring IV fluids
- Hemodynamic instability
- Inability to tolerate oral intake
- Disseminated disease (encephalitis, hepatitis, multi-organ involvement)
- Significant electrolyte derangements
- Severe wasting/malnutrition requiring inpatient nutritional support
Discharge criteria
- Tolerating oral fluids and medications
- Hemodynamically stable
- Electrolytes corrected
- Outpatient follow-up arranged with infectious disease
Observation indications
- Moderate dehydration responding to IV fluids
- Diagnostic uncertainty requiring further workup
Specialist consultation triggers
- Infectious disease — all confirmed cases, especially HIV-associated or disseminated disease [2]
- Ophthalmology — any suspected ocular involvement [3]
- GI/Endoscopy — chronic diarrhea >2 months with negative stool workup [3]
- CDC consultation — for speciation via PCR and guidance on rare species [3]
18. Follow Up / Return Precautions
Follow-up timing
- Infectious disease follow-up within 1–2 weeks of diagnosis
- Repeat CD4 count and viral load per ART monitoring schedule
- Stool re-examination to confirm clearance after treatment [3]
- Ophthalmology follow-up for ocular disease until resolution confirmed
Symptoms requiring immediate reassessment
- Worsening or bloody diarrhea
- Inability to keep down fluids
- Dizziness, syncope, or signs of severe dehydration
- New visual changes or eye pain
- Confusion, seizures, or new neurologic symptoms
- High fevers (consider alternative/co-infection)
Patient counseling
- Strict hand hygiene and safe water practices to prevent reinfection [2-3]
- ART adherence is the single most important factor for cure — immune reconstitution leads to clearance [2-3]
- Expected recovery: symptoms typically improve within 1 month of effective ART; organism eradication by 6 months [3]
- Secondary prophylaxis with albendazole may be continued until sustained immune reconstitution (CD4 >200 for ≥3 months) [2-3]
References
1. Microsporidiosis in Humans. — Han B, Pan G, Weiss LM. Clinical Microbiology Reviews. 2021.
2. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
3. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
4. Microsporidial Infections in Immunodeficient and Immunocompetent Patients. — Weber R, Bryan RT. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 1994.
5. Prevalence and Individualized Risk Factors of E. Bieneusi and E. Intestinalis Infections Among People Living With HIV (PLHIV) With Diarrhea in Ecuador: Insights From a Single-Center Cross-Sectional Study. — Pazmiño-Gómez BJ, Rodas-Pazmiño J, Guevara-Viejó F, et al. Journal of Clinical Medicine. 2025.
6. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. — Shane AL, Mody RK, Crump JA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017.
7. Molecular Detection of Intestinal Protozoa and Microsporidia in HIV/AIDS Patients. — Yurekturk S, Cakırca TD, Gurbuz E, Aydemir S, Ekici A. Diagnostic Microbiology and Infectious Disease. 2025.
8. Pragmatic Combination of Available Diagnostic Tools for Optimal Detection of Intestinal Microsporidia. — Kaushik S, Saha R, Das S, Ramachandran VG, Goel A. Advances in Experimental Medicine and Biology. 2017.
9. Comparison of Staining Techniques and Multiplex Nested PCR for Diagnosis of Intestinal Microsporidiosis. — Saigal K, Khurana S, Sharma A, Sehgal R, Malla N. Diagnostic Microbiology and Infectious Disease. 2013.
10. Comparison of Three Staining Methods for Detecting Microsporidia in Fluids. — Didier ES, Orenstein JM, Aldras A, et al. Journal of Clinical Microbiology. 1995.
11. Workup of Gastrointestinal Microsporidiosis. — Conteas CN, Didier ES, Berlin OG. Digestive Diseases. 1998.
12. Invasion of Host Cells by Microsporidia. — Han B, Takvorian PM, Weiss LM. Frontiers in Microbiology. 2020.